TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24448757

Group type: EXPERIMENTAL
Intervention: Cystone supplement with cisplatin (group B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cisplatin without cystone (group A)
Number of subjects: 49
Study: 21900941

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 1316
Study: 20492052

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 18954260

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17214048

Group type: EXPERIMENTAL
Intervention: Manual fetal stimulation (MST)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Nonstress test (NST)
Number of subjects: 540
Study: 12488271

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional AEDs
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 17
Study: 11022177

Group type: EXPERIMENTAL
Intervention: Nasal octreotide (for at least 9 to 12 months); n=42
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (mean exposure of 3 years); n=231
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Intramuscular Sandostatin LAR (mean exposure of 2.5 years); n=47
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: All populations (including n=141 for cross-reaction testing)
Number of subjects: 442
Study: 8637792

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS) during prefeeding
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no NNS)
Number of subjects: 13
Study: 1517612

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 81/minute during Phase I
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 5.61/minute during Phase II
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both phases
Number of subjects: 15
Study: 6475984

Group type: EXPERIMENTAL
Intervention: Moxalactam plus piperacillin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Moxalactam plus amikacin
Number of subjects: 136
Study: 30122328

Group type: EXPERIMENTAL
Intervention: 8-weeks of interval exercise at 60%-75% Wattpeak
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 66
Study: 30004914

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block with placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 26655924

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hypocaloric diet (HC diet)
Number of subjects: 27
Study: 24625010

Group type: EXPERIMENTAL
Intervention: Observational Pain Management Protocol (Protocol) implemented for 12 weeks after 4 weeks of baseline assessment and staff training.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual pain management strategies in control care homes.
Number of subjects: 122
Study: 22183078

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.15 mmol/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.20 mmol/kg)
Number of subjects: 20
Study: 20088738

Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CAP + Ozone (O3)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 23
Study: 18836324

Group type: EXPERIMENTAL
Intervention: Bensal HP (QRB7)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream (SSC)
Number of subjects: 40
Study: 16297752

Group type: EXPERIMENTAL
Intervention: 10-cm group (threading the epidural catheter 10 cm then retracting 5 cm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5-cm group (threading the epidural catheter 5 cm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10-cm group
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5-cm group
Number of subjects: 80
Study: 11939922

Group type: EXPERIMENTAL
Intervention: CO2‐pneumoperitoneum (13 mmHg) in supine position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CO2‐pneumoperitoneum (13 mmHg) in head-up position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CO2‐pneumoperitoneum (13 mmHg) in head-down position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Head-down position with pneumoperitoneum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (supine, head-up, head-down)
Number of subjects: 30
Study: 10225478

Group type: EXPERIMENTAL
Intervention: ACE-Inhibitors
Number of subjects: 35

Group type: COMPARATOR
Intervention: beta-blockers
Number of subjects: 35

Group type: COMPARATOR
Intervention: calcium antagonists
Number of subjects: 35

Group type: COMPARATOR
Intervention: no pharmacological treatment
Number of subjects: 35
Study: 8550304

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intramuscular (IM) injections of narcotics
Number of subjects: 26
Study: 2142901

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 95728

Group type: EXPERIMENTAL
Intervention: Minoxidil in combination with propranolol and diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other drugs (comparable group)
Number of subjects: 0
Study: 30040002

Group type: EXPERIMENTAL
Intervention: Polarized training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Threshold training
Number of subjects: 22
Study: 28617838

Group type: EXPERIMENTAL
Intervention: 2 mg tesamorelin
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study: 25773683

Group type: EXPERIMENTAL
Intervention: Nutrition Education (NE) program for 6 months
Number of subjects: 130
Study: 23975476

Group type: EXPERIMENTAL
Intervention: Fluoxetine (directly observed treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral to a local public mental health clinic (control)
Number of subjects: 0
Study: 21256308

Group type: EXPERIMENTAL
Intervention: Leukocyte filters on both arterial and cardioplegia lines
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard arterial filters
Number of subjects: 82
Study: 18989717

Group type: EXPERIMENTAL
Intervention: Diacylglycerol (DAG) supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: TAG oil (control)
Number of subjects: 7
Study: 16815689

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin (2 g i.v. over 0.5 h as a loading dose followed by 8 g i.v. daily over 24 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin (3 g i.v. every 6h over 0.5 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin
Number of subjects: 40
Study: 15049402

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg tablet once daily for 2 weeks
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1862
Study: 11819866

Group type: EXPERIMENTAL
Intervention: Qiwei Baizhu Powder (QWBZP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Qiwei Baizhu Powder (QWBZP) in animal models
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (ORS in animal models)
Number of subjects: 83
Study: 9491825

Group type: EXPERIMENTAL
Intervention: Bilateral forearm plethysmography (FBF ratios) at rest
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unilateral forearm plethysmography (FBF) at rest
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bilateral forearm plethysmography (FBF ratios) after ipsilateral exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unilateral forearm plethysmography (FBF) after ipsilateral exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bilateral forearm plethysmography (FBF ratios) 20 min after exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unilateral forearm plethysmography (FBF) 20 min after exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bilateral forearm vascular resistance (FVR) ratio
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (FBF ratios)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Angiotensin II infusion (FBF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (FBF ratios)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Noradrenaline infusion (FBF)
Number of subjects: 9
Study: 7828793

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg b.i.d.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg b.i.d.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3144615

Group type: COMPARATOR
Intervention: Short-term MF chemotherapy (mitomycin C 0.04 mg/kg plus 5-fluorouracil 5.0 mg/kg x 6 bolus i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MF plus long-term HCFU chemotherapy (HCFU 6-12 mg/kg/day over 12 weeks, p.o.)
Number of subjects: 0
Study: 30113526

Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Perindopril (10 mg daily)
Number of subjects: 30
Study: 28463633

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (RIC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 129
Study: 25526832

Group type: EXPERIMENTAL
Intervention: Immediate Treatment (IT) group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 24
Study: 23385285

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m), Carboplatin (6 times AUC), Vorinostat (200 mg) every 28 days for 6 cycles
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m) and Vorinostat (400 mg) maintenance chemotherapy every 28 days for 12 cycles
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Primary induction chemotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Severe gastrointestinal events
Number of subjects: 18
Study: 20951505

Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radioTherapy (Targit) boost with a single dose of 20 Gy
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radioTherapy (Targit) boost
Number of subjects: 299
Study: 18270182

Group type: EXPERIMENTAL
Intervention: Luteal phase support continued for 3 weeks after first ultrasound (Group A)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Luteal phase support stopped on the day of first ultrasound (Group B)
Number of subjects: 257
Study: 17236593

Group type: EXPERIMENTAL
Intervention: rhGH 0.15 U/kg daily from day 3 to day 9 after operation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12895016

Group type: EXPERIMENTAL
Intervention: Group therapy based on a two‐stage model of trauma treatment including Dialectical Behavior Therapy skills and writing assignments
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-contact comparison condition
Number of subjects: 24
Study: 11198553

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 9751910

Group type: EXPERIMENTAL
Intervention: 75 microg/kg each of morphine and midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 75 microg/kg morphine and 50 microg/kg midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 50 microg/kg morphine and 75 microg/kg midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 50 microg/kg each of morphine and midazolam
Number of subjects: 80
Study: 8455175

Group type: EXPERIMENTAL
Intervention: Adjustments to remove significant slides and nonworking-side interferences
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mock occlusal adjustment
Number of subjects: 51
Study: 3940501

Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg/d) + Metoclopramide (40 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cimetidine (1200 mg/d) + Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cimetidine + Metoclopramide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cimetidine + Placebo
Number of subjects: 25
Study: 29512308

Group type: EXPERIMENTAL
Intervention: Occlusion trial (arterial occlusion applied during recovery)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control trial (no arterial occlusion applied during recovery)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Occlusion trial
Number of subjects: 45
Study: 26984513

Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) program, 0.5-1 hour duration at least twice weekly for at least 3 months, with continuation encouraged thereafter.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) program
Number of subjects: 45
Study: 25516338

Group type: EXPERIMENTAL
Intervention: Pemetrexed-Carboplatin-Bevacizumab (PemCBev)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Academic vs Community settings
Number of subjects: 94
Study: 22951014

Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg b.i.d. in combination with two-drug platinum-based chemotherapy
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo in combination with two-drug platinum-based chemotherapy
Number of subjects: 316
Study: 19960257

Group type: EXPERIMENTAL
Intervention: Triple therapy with amantadine (200 mg daily)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Double therapy (peginterferon alpha-2a plus weight-based ribavirin for 48 weeks)
Number of subjects: 124
Study: 18256841

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment via intravitreal administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring with Optical Coherence Tomography (OCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical follow-up and visual acuity assessment
Number of subjects: 0
Study: 16202046

Group type: EXPERIMENTAL
Intervention: Lingual plate-type RPDs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lingual bar-type RPDs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both RPD types
Number of subjects: 36
Study: 12465698

Group type: EXPERIMENTAL
Intervention: Double dose (DD) of normal-release morphine at bedtime
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single dose (SD) of normal-release morphine at bedtime
Number of subjects: 20
Study: 10709388

Group type: EXPERIMENTAL
Intervention: Ketorolac, 60 mg i.v.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propacetamol, 2 g i.v.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol, 200 mg i.v.
Number of subjects: 60
Study: 7491837

Group type: EXPERIMENTAL
Intervention: Transdermal ERT (50 micrograms 17‐beta‐estradiol/24 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral ERT (0.6 mg conjugated estrogens + 5 mg medrogestone on days 11-21 for three cycles)
Number of subjects: 42
Study: 2109336

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analog
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7379334

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31315240

Group type: EXPERIMENTAL
Intervention: National telephone counselling for smoking cessation
Number of subjects: 469
Study: 28031424

Group type: EXPERIMENTAL
Intervention: Dalantercept 0.6, 0.9, or 1.2 mg/kg subcutaneously every 3 weeks plus axitinib 5 mg by mouth twice daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dalantercept plus axitinib
Number of subjects: 29
Study: 26020821

Group type: EXPERIMENTAL
Intervention: Rebamipide ophthalmic suspension
Number of subjects: 30
Study: 24382318

Group type: EXPERIMENTAL
Intervention: Educational mental health intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 59
Study: 22180255

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 48
Study: 19683731

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (1.3, 2.9 or 3.9 mg daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Oral oxybutynin (5, 10 or 15 mg daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Transdermal oxybutynin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 57
Study: 17997936

Group type: EXPERIMENTAL
Intervention: Conventional needle acupuncture
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham acupuncture (without skin penetration)
Number of subjects: 99
Study: 11045862

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 7.5, 15, 22.5, and 30 mg bid
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 8960715

Group type: EXPERIMENTAL
Intervention: Gabapentin (800 mg, t.i.d.)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 1552095

Group type: COMPARATOR
Intervention: Quinidine (1,500 mg/day for days 1-3, then 1,500 mg + verapamil 240 mg/day for days 4-6)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quinidine and Verapamil (1,500 mg + 240 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amiodarone (1,200 mg/day intravenously for days 1-3, then 800 mg/day orally for days 4-14)
Number of subjects: 40
Study: 3888731

Group type: EXPERIMENTAL
Intervention: Once daily treatment with 1% tioconazole cream
Number of subjects: 205

Group type: COMPARATOR
Intervention: Twice daily treatment with 1% tioconazole cream
Number of subjects: 205
Study: 31306390

Group type: EXPERIMENTAL
Intervention: Inactivated Bacillus coagulans (iBC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study: 29746891

Group type: EXPERIMENTAL
Intervention: Green tea extract (500 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26702991

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg, Bicalutamide 50 mg daily, and Tamoxifen 10 mg daily for 3 months (D + B group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LHRH agonists and Bicalutamide daily for 1 month (LHRH group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dutasteride and Bicalutamide (D + B group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LHRH agonists
Number of subjects: 60
Study: 23895176

Group type: EXPERIMENTAL
Intervention: 1 : 80 000 epinephrine concentration in 2% lidocaine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1 : 200 000 epinephrine concentration in 2% lidocaine
Number of subjects: 62
Study: 23116437

Group type: COMPARATOR
Intervention: Cemented THR
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Reverse Hybrid THR
Number of subjects: 51
Study: 20386431

Group type: EXPERIMENTAL
Intervention: Weight-adjusted dalteparin (WAD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 39
Study: 18777847

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16401307

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12634965

Group type: EXPERIMENTAL
Intervention: 99mTc-interleukin-2 scintigraphy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO labelled granulocytes scintigraphy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both 99mTc-interleukin-2 and 99mTc-HMPAO scintigraphy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO scintigraphy
Number of subjects: 29
Study: 10666820

Group type: EXPERIMENTAL
Intervention: Phlogenzym
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzymes
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study: 8918967

Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation protocol including aerobic arm training sessions (Group A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional rehabilitation program (Group B)
Number of subjects: 8
Study: 1888238

Group type: EXPERIMENTAL
Intervention: Marine oil capsules (4.5 g of omega-3 fatty acids, or nine to 18 capsules daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marine oil capsules
Number of subjects: 0
Study: 31892609

Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10,000 IU vitamin D3/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All doses of vitamin D3
Number of subjects: 0
Study: 29462639

Group type: EXPERIMENTAL
Intervention: Experimental group (received explicit instruction to avoid any unwanted finger movements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no explicit instruction to avoid unwanted finger movements)
Number of subjects: 0
Study: 27488390

Group type: EXPERIMENTAL
Intervention: The GOOD life intervention (social norms components including face-to-face communication, print communication, and interactive media)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1400
Study: 25376940

Group type: EXPERIMENTAL
Intervention: BIS‐guided fluid management
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fluid management based only on clinical information
Number of subjects: 138